ANASTASIA KIMANTHI: Open Payments
NPI 1801523485 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,996 in 134 payments from 12 companies in 2025. Trend: 2023 $452 · 2024 $2,033 · 2025 $2,996
Food & beverage: $2,996
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 19 | $726 |
| Teva Pharmaceuticals USA, Inc. | 22 | $522 |
| Janssen Pharmaceuticals, Inc | 22 | $424 |
| Vanda Pharmaceuticals Inc. | 15 | $308 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $254 |
| ABBVIE INC. | 7 | $184 |
| Axsome Therapeutics, Inc. | 3 | $154 |
| E.R. Squibb & Sons, L.L.C. | 13 | $149 |
| Alkermes, Inc. | 5 | $95 |
| Lundbeck LLC | 5 | $83 |
Products named: INGREZZA, INVEGA SUSTENNA, FANAPT, AUSTEDO XR, CAPLYTA, UZEDY, VRAYLAR, Auvelity.
Industry payments across TX — which companies pay providers there.
